Retinoid pathway and cancer therapeutics

Advanced Drug Delivery Reviews

Volumn 62, Issue 13, 2010, Pages 1285-1298

  Bushue, Nathan ^a   Wan, Yu Jui Yvonne ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

13 cis retinoic acid; 9 cis retinoic acid; All trans retinoic acid; Nuclear receptor; RAR; Retinoids; RXR

Indexed keywords

ALL-TRANS RETINOIC ACIDS; NUCLEAR RECEPTORS; RAR; RETINOIC ACIDS; RETINOIDS; RXR;

CELL DEATH; TRANSCRIPTION FACTORS;

ACIDS;

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ALITRETINOIN; ALPHA TOCOPHEROL; ANHYDRORETINOL; ANTINEOPLASTIC AGENT; BETA CAROTENE; BEXAROTENE; CELLULAR RETINOIC ACID BINDING PROTEIN I; CELLULAR RETINOIC ACID BINDING PROTEIN II; CELLULAR RETINOL BINDING PROTEIN; DEXAMETHASONE; FENRETINIDE; ISOETRETIN; ISOPROTEIN; ISOTRETINOIN; NUCLEAR RECEPTOR NUR77; PLACEBO; PROTEIN STRA6; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID BINDING PROTEIN; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOL BINDING PROTEIN; RETINOL PALMITATE; TAMOXIFEN; TAZAROTENE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR;

ACNE; AMYOTROPHIC LATERAL SCLEROSIS; ASTHENIA; ASTHMA; ATROPHY; BASAL CELL CARCINOMA; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; COLON CANCER; COMEDO; CUSHING DISEASE; CUTANEOUS T CELL LYMPHOMA; DIETARY INTAKE; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; ECZEMA; EMPHYSEMA; EWING SARCOMA; FACE CANCER; FATTY LIVER; GENE EXPRESSION REGULATION; GENOMICS; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; INSULIN RESISTANCE; KAPOSI SARCOMA; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; MOUTH CANCER; NEUROBLASTOMA; NONHUMAN; OBESITY; OVARY CANCER; PENIS CANCER; PRECANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSORIASIS; RETINOIC ACID SYNDROME; REVIEW; ROSACEA; SCHIZOPHRENIA; SKIN CANCER; SKIN DEFECT; SKIN DISEASE; THYROID CANCER; THYROID TUMOR; UTERINE CERVIX CANCER; VERRUCA VULGARIS; VISUAL DISORDER; VITAMIN INTAKE;

ANIMALS; CELL DIFFERENTIATION; HUMANS; NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; RETINOL-BINDING PROTEINS; RETINOL-BINDING PROTEINS, CELLULAR; TRETINOIN; VITAMIN A;

EID: 78649334751     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.07.003     Document Type: Review

References (207)

1. Lanska D.J. Chapter 29 historical aspects of the major neurological vitamin deficiency disorders overview and fat-soluble vitamin A. Handb. Clin. Neurol. 2009, 95:435-444.
2. Voss H.E., Lunin Nicolai I. 1853-1937; a biographical assay. J. Am. Diet. Assoc. 1956, 32:317-320.
3. Napoli J.L. Biochemical pathways of retinoid transport, metabolism, and signal transduction. Clin. Immunol. Immunopathol. 1996, 80:S52-S62.
4. Achkar C.C., Derguini F., Blumberg B., Langston A., Levin A.A., Speck J., Evans R.M., Bolado J., Nakanishi K., Buck J., Gudas L.J. 4-oxoretinol, a new natural ligand and transactivator of the retinoic acid receptors. Proc. Natl Acad. Sci. USA 1996, 93:4879-4884.
5. Buck J., Derguini F., Levi E., Nakanishi K., Hammerling U. Intracellular signaling by 14-hydroxy-4, 14-retro-retinol. Science 1991, 254:1654-1656.
6. Altucci L., Leibowitz M.D., Ogilvie K.M., de Lera A.R., Gronemeyer H. RAR and RXR modulation in cancer and metabolic disease. Nat. Rev. Drug Discov. 2007, 6:793-810.
7. de Lera A.R., Bourguet W., Altucci L., Gronemeyer H. Design of selective nuclear receptor modulators: RAR and RXR as a case study. Nat. Rev. Drug Discov. 2007, 6:811-820.
8. Barnard J.H., Collings J.C., Whiting A., Przyborski S.A., Marder T.B. Synthetic retinoids: structure-activity relationships. Chemistry 2009, 15:11430-11442.
9. Wolf G. Identification of a membrane receptor for retinol-binding protein functioning in the cellular uptake of retinol. Nutr. Rev. 2007, 65:385-388.
10. Zanotti G., Berni R. Plasma retinol-binding protein: structure and interactions with retinol, retinoids, and transthyretin. Vitam. Horm. 2004, 69:271-295.
11. Yang Q., Graham T.E., Mody N., Preitner F., Peroni O.D., Zabolotny J.M., Kotani K., Quadro L., Kahn B.B. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005, 436:356-362.
12. Seeliger M.W., Biesalski H.K., Wissinger B., Gollnick H., Gielen S., Frank J., Beck S., Zrenner E. Phenotype in retinol deficiency due to a hereditary defect in retinol binding protein synthesis. Invest. Ophthalmol. Vis. Sci. 1999, 40:3-11.
13. Manolescu D.C., Sima A., Bhat P.V. All-trans retinoic acid lowers serum retinol-binding protein 4 concentrations and increases insulin sensitivity in diabetic mice. J. Nutr. 2010, 140:311-316.
14. Kawaguchi R., Yu J., Honda J., Hu J., Whitelegge J., Ping P., Wiita P., Bok D., Sun H. A membrane receptor for retinol binding protein mediates cellular uptake of vitamin A. Science 2007, 315:820-825.
15. Szeto W., Jiang W., Tice D.A., Rubinfeld B., Hollingshead P.G., Fong S.E., Dugger D.L., Pham T., Yansura D.G., Wong T.A., Grimaldi J.C., Corpuz R.T., Singh J.S., Frantz G.D., Devaux B., Crowley C.W., Schwall R.H., Eberhard D.A., Rastelli L., Polakis P., Pennica D. Overexpression of the retinoic acid-responsive gene Stra6 in human cancers and its synergistic induction by Wnt-1 and retinoic acid. Cancer Res. 2001, 61:4197-4205.
16. Pasutto F., Sticht H., Hammersen G., Gillessen-Kaesbach G., Fitzpatrick D.R., Nurnberg G., Brasch F., Schirmer-Zimmermann H., Tolmie J.L., Chitayat D., Houge G., Fernandez-Martinez L., Keating S., Mortier G., Hennekam R.C., von der Wense A., Slavotinek A., Meinecke P., Bitoun P., Becker C., Nurnberg P., Reis A., Rauch A. Mutations in STRA6 cause a broad spectrum of malformations including anophthalmia, congenital heart defects, diaphragmatic hernia, alveolar capillary dysplasia, lung hypoplasia, and mental retardation. Am. J. Hum. Genet. 2007, 80:550-560.
17. Albalat R. The retinoic acid machinery in invertebrates: ancestral elements and vertebrate innovations. Mol. Cell. Endocrinol. 2009, 313:23-35.
18. Ghyselinck N.B., Bavik C., Sapin V., Mark M., Bonnier D., Hindelang C., Dierich A., Nilsson C.B., Hakansson H., Sauvant P., Azais-Braesco V., Frasson M., Picaud S., Chambon P. Cellular retinol-binding protein I is essential for vitamin A homeostasis. EMBO J. 1999, 18:4903-4914.
19. Zhang X.E.L., Lu J., Tso P., Blaner W.S., Levin M.S., Li E. Increased neonatal mortality in mice lacking cellular retinol-binding protein II. J. Biol. Chem. 2002, 277:36617-36623.
20. Piantedosi R., Ghyselinck N., Blaner W.S., Vogel S. Cellular retinol-binding protein type III is needed for retinoid incorporation into milk. J. Biol. Chem. 2005, 280:24286-24292.
21. Esteller M., Guo M., Moreno V., Peinado M.A., Capella G., Galm O., Baylin S.B., Herman J.G. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res. 2002, 62:5902-5905.
22. Matt N., Schmidt C.K., Dupe V., Dennefeld C., Nau H., Chambon P., Mark M., Ghyselinck N.B. Contribution of cellular retinol-binding protein type 1 to retinol metabolism during mouse development. Dev. Dyn. 2005, 233:167-176.
23. Fawcett D., Pasceri P., Fraser R., Colbert M., Rossant J., Giguere V. Postaxial polydactyly in forelimbs of CRABP-II mutant mice. Development 1995, 121:671-679.
24. Wolf G. Cellular retinoic acid-binding protein II: a coactivator of the transactivation by the retinoic acid receptor complex RAR.RXR. Nutr. Rev. 2000, 58:151-153.
25. Noy N. Retinoid-binding proteins: mediators of retinoid action. Biochem. J. 2000, 348(Pt 3):481-495.
26. Blaese M.A., Santo-Hoeltje L., Rodemann H.P. CRABP I expression and the mediation of the sensitivity of human tumour cells to retinoic acid and irradiation. Int. J. Radiat. Biol. 2003, 79:981-991.
27. Petkovich M., Brand N.J., Krust A., Chambon P. A human retinoic acid receptor which belongs to the family of nuclear receptors. Nature 1987, 330:444-450.
28. Giguere V., Ong E.S., Segui P., Evans R.M. Identification of a receptor for the morphogen retinoic acid. Nature 1987, 330:624-629.
29. Sporn M.B., Roberts A.B. Role of retinoids in differentiation and carcinogenesis. Cancer Res. 1983, 43:3034-3040.
30. Heyman R.A., Mangelsdorf D.J., Dyck J.A., Stein R.B., Eichele G., Evans R.M., Thaller C. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor. Cell 1992, 68:397-406.
31. Forsmo S., Fjeldbo S.K., Langhammer A. Childhood cod liver oil consumption and bone mineral density in a population-based cohort of peri- and postmenopausal women: the Nord-Trondelag Health Study. Am. J. Epidemiol. 2008, 167:406-411.
32. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
33. Wang K., Chen S., Xie W., Wan Y.J. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem. Pharmacol. 2008, 75:2204-2213.
34. Chen S., Wang K., Wan Y.J. Retinoids activate RXR/CAR-mediated pathway and induce CYP3A. Biochem. Pharmacol. 2010, 79:270-276.
35. Wang K., Mendy A.J., Dai G., Luo H.R., He L., Wan Y.J. Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol. Sci. 2006, 92:51-60.
36. Wan Y.J., An D., Cai Y., Repa J.J., Hung-Po Chen T., Flores M., Postic C., Magnuson M.A., Chen J., Chien K.R., French S., Mangelsdorf D.J., Sucov H.M. Hepatocyte-specific mutation establishes retinoid X receptor alpha as a heterodimeric integrator of multiple physiological processes in the liver. Mol. Cell. Biol. 2000, 20:4436-4444.
37. Wan Y.J., Cai Y., Lungo W., Fu P., Locker J., French S., Sucov H.M. Peroxisome proliferator-activated receptor alpha-mediated pathways are altered in hepatocyte-specific retinoid X receptor alpha-deficient mice. J. Biol. Chem. 2000, 275:28285-28290.
38. M. Gyamfi and Y. J. Wan, Pathogenesis of alcoholic liver diseasse: the role of nuclear receptors., Exp. Biol. Med. 235 (2010) 547-560.
39. Schug T.T., Berry D.C., Shaw N.S., Travis S.N., Noy N. Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors. Cell 2007, 129:723-733.
40. Berry D.C., Noy N. All-trans-retinoic acid represses obesity and insulin resistance by activating both peroxisome proliferation-activated receptor beta/delta and retinoic acid receptor. Mol. Cell. Biol. 2009, 29:3286-3296.
41. Brocard J., Kastner P., Chambon P. Two novel RXR alpha isoforms from mouse testis. Biochem. Biophys. Res. Commun. 1996, 229:211-218.
42. Dolle P. Developmental expression of retinoic acid receptors (RARs). Nucl. Recept. Signal. 2009, 7:e006.
43. Lufkin T., Lohnes D., Mark M., Dierich A., Gorry P., Gaub M.P., LeMeur M., Chambon P. High postnatal lethality and testis degeneration in retinoic acid receptor alpha mutant mice. Proc. Natl Acad. Sci. USA 1993, 90:7225-7229.
44. Ghyselinck N.B., Dupe V., Dierich A., Messaddeq N., Garnier J.M., Rochette-Egly C., Chambon P., Mark M. Role of the retinoic acid receptor beta (RARbeta) during mouse development. Int. J. Dev. Biol. 1997, 41:425-447.
45. Lohnes D., Kastner P., Dierich A., Mark M., LeMeur M., Chambon P. Function of retinoic acid receptor gamma in the mouse. Cell 1993, 73:643-658.
46. Sucov H.M., Dyson E., Gumeringer C.L., Price J., Chien K.R., Evans R.M. RXR alpha mutant mice establish a genetic basis for vitamin A signaling in heart morphogenesis. Genes Dev. 1994, 8:1007-1018.
47. Kastner P., Grondona J.M., Mark M., Gansmuller A., LeMeur M., Decimo D., Vonesch J.L., Dolle P., Chambon P. Genetic analysis of RXR alpha developmental function: convergence of RXR and RAR signaling pathways in heart and eye morphogenesis. Cell 1994, 78:987-1003.
48. Sucov H.M., Izpisua-Belmonte J.C., Ganan Y., Evans R.M. Mouse embryos lacking RXR alpha are resistant to retinoic-acid-induced limb defects. Development 1995, 121:3997-4003.
49. Kastner P., Mark M., Leid M., Gansmuller A., Chin W., Grondona J.M., Decimo D., Krezel W., Dierich A., Chambon P. Abnormal spermatogenesis in RXR beta mutant mice. Genes Dev. 1996, 10:80-92.
50. Mascrez B., Ghyselinck N.B., Watanabe M., Annicotte J.S., Chambon P., Auwerx J., Mark M. Ligand-dependent contribution of RXRbeta to cholesterol homeostasis in Sertoli cells. EMBO Rep. 2004, 5:285-290.
51. Brown N.S., Smart A., Sharma V., Brinkmeier M.L., Greenlee L., Camper S.A., Jensen D.R., Eckel R.H., Krezel W., Chambon P., Haugen B.R. Thyroid hormone resistance and increased metabolic rate in the RXR-gamma-deficient mouse. J. Clin. Invest. 2000, 106:73-79.
52. Mark M., Ghyselinck N.B., Chambon P. Function of retinoic acid receptors during embryonic development. Nucl. Recept. Signal. 2009, 7:e002.
53. Fanjul A., Dawson M.I., Hobbs P.D., Jong L., Cameron J.F., Harlev E., Graupner G., Lu X.P., Pfahl M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994, 372:107-111.
54. Austenaa L.M., Carlsen H., Ertesvag A., Alexander G., Blomhoff H.K., Blomhoff R. Vitamin A status significantly alters nuclear factor-kappaB activity assessed by in vivo imaging. FASEB J. 2004, 18:1255-1257.
55. Liao Y.P., Ho S.Y., Liou J.C. Non-genomic regulation of transmitter release by retinoic acid at developing motoneurons in Xenopus cell culture. J. Cell Sci. 2004, 117:2917-2924.
56. Chen N., Onisko B., Napoli J.L. The nuclear transcription factor RAR? associates with neuronal RNA granules and suppresses translation. J. Biol. Chem. 2008, 283:20841-20847.
57. Masia S., Alvarez S., de Lera A.R., Barettino D. Rapid, nongenomic actions of retinoic acid on phosphatidylinositol-3-kinase signaling pathway mediated by the retinoic acid receptor. Mol. Endocrinol. 2007, 21:2391-2402.
58. Chen N., Napoli J.L. All-trans-retinoic acid stimulates translation and induces spine formation in hippocampal neurons through a membrane-associated RARalpha. FASEB J. 2008, 22:236-245.
59. Poon M.M., Chen L. Retinoic acid-gated sequence-specific translational control by RARalpha. Proc. Natl Acad. Sci. USA 2008, 105:20303-20308.
60. Aggarwal S., Kim S.W., Cheon K., Tabassam F.H., Yoon J.H., Koo J.S. Nonclassical action of retinoic acid on the activation of the cAMP response element-binding protein in normal human bronchial epithelial cells. Mol. Biol. Cell 2006, 17:566-575.
61. Sun S.Y., Lotan R. Retinoids and their receptors in cancer development and chemoprevention. Crit. Rev. Oncol. Hematol. 2002, 41:41-55.
62. Bukhari M.H., Qureshi S.S., Niazi S., Asef M., Naheed M., Khan S.A., Chaudhry N.A., Tayyab M., Hasan M. Chemotherapeutic/chemopreventive role of retinoids in chemically induced skin carcinogenesis in albino mice. Int. J. Dermatol. 2007, 46:1160-1165.
63. Wang Y., Wen W., Yi Y., Zhang Z., Lubet R.A., You M. Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer. Cancer Prev. Res. 2009, 2:1059-1064. (Phila Pa).
64. Pisano C., Vesci L., Fodera R., Ferrara F.F., Rossi C., De Cesare M., Zuco V., Pratesi G., Supino R., Zunino F. Antitumor activity of the combination of synthetic retinoid ST1926 and cisplatin in ovarian carcinoma models. Ann. Oncol. 2007, 18:1500-1505.
65. Shah R.K., Valdez T.A., Wang Z., Shapshay S.M. Pulsed-dye laser and retinoic acid delay progression of oral squamous cell carcinoma: a murine model. Laryngoscope 2001, 111:1203-1208.
66. Li Y., Zhang Y., Hill J., Kim H.T., Shen Q., Bissonnette R.P., Lamph W.W., Brown P.H. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. Br. J. Cancer 2008, 98:1380-1388.
67. Moon R.C., Kelloff G.J., Detrisac C.J., Steele V.E., Thomas C.F., Sigman C.C. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res. 1994, 14:5-11.
68. Liu B., Lee K.W., Li H., Ma L., Lin G.L., Chandraratna R.A., Cohen P. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin. Cancer Res. 2005, 11:4851-4856.
69. Muto Y., Moriwaki H., Shiratori Y. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Digestion 1998, 59(Suppl 2):89-91.
70. Recchia F., Sica G., Candeloro G., Necozione S., Bisegna R., Bratta M., Rea S. Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: long-term follow-up of a phase II study. Oncol. Rep. 2009, 21:1011-1016.
71. Edelman M.J., Smith R., Hausner P., Doyle L.A., Kalra K., Kendall J., Bedor M., Bisaccia S. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J. Clin. Oncol. 2005, 23:5774-5778.
72. Yamane A., Tsukamoto N., Saitoh T., Uchiumi H., Handa H., Karasawa M., Nojima Y., Murakami H. Successful treatment by all-trans retinoic acid in a patient with acute promyelocytic leukemia complicated by liver cirrhosis and polycystic kidney. Intern. Med. 2009, 48:1691-1694.
73. Colombo N., Formelli F., Cantu M.G., Parma G., Gasco M., Argusti A., Santinelli A., Montironi R., Cavadini E., Baglietto L., Guerrieri-Gonzaga A., Viale G., Decensi A. A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer. Cancer Epidemiol. Biomarkers Prev. 2006, 15:1914-1919.
74. Borrow J., Goddard A.D., Sheer D., Solomon E. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science 1990, 249:1577-1580.
75. de The H., Chomienne C., Lanotte M., Degos L., Dejean A. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor alpha gene to a novel transcribed locus. Nature 1990, 347:558-561.
76. Grignani F., De Matteis S., Nervi C., Tomassoni L., Gelmetti V., Cioce M., Fanelli M., Ruthardt M., Ferrara F.F., Zamir I., Seiser C., Lazar M.A., Minucci S., Pelicci P.G. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 1998, 391:815-818.
77. Fenrick R., Hiebert S.W. Role of histone deacetylases in acute leukemia. J. Cell. Biochem. Suppl. 1998, 30-31:194-202.
78. Zeisig B.B., Kwok C., Zelent A., Shankaranarayanan P., Gronemeyer H., Dong S., So C.W. Recruitment of RXR by homotetrameric RARalpha fusion proteins is essential for transformation. Cancer Cell 2007, 12:36-51.
79. Zhu J., Nasr R., Peres L., Riaucoux-Lormiere F., Honore N., Berthier C., Kamashev D., Zhou J., Vitoux D., Lavau C., de The H. RXR is an essential component of the oncogenic PML/RARA complex in vivo. Cancer Cell 2007, 12:23-35.
80. Yoshida H., Kitamura K., Tanaka K., Omura S., Miyazaki T., Hachiya T., Ohno R., Naoe T. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway. Cancer Res. 1996, 56:2945-2948.
81. Casini T., Pelicci P.G. A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene 1999, 18:3235-3243.
82. Jimenez-Lara A.M., Clarke N., Altucci L., Gronemeyer H. Retinoic-acid-induced apoptosis in leukemia cells. Trends Mol. Med. 2004, 10:508-515.
83. Patatanian E., Thompson D.F. Retinoic acid syndrome: a review. J. Clin. Pharm. Ther. 2008, 33:331-338.
84. Christov K.T., Moon R.C., Lantvit D.D., Boone C.W., Steele V.E., Lubet R.A., Kelloff G.J., Pezzuto J.M. 9-cis-retinoic acid but not 4-(hydroxyphenyl)retinamide inhibits prostate intraepithelial neoplasia in Noble rats. Cancer Res. 2002, 62:5178-5182.
85. Wu K., Kim H.T., Rodriquez J.L., Munoz-Medellin D., Mohsin S.K., Hilsenbeck S.G., Lamph W.W., Gottardis M.M., Shirley M.A., Kuhn J.G., Green J.E., Brown P.H. 9-cis-Retinoic acid suppresses mammary tumorigenesis in C3(1)-simian virus 40T antigen-transgenic mice. Clin. Cancer Res. 2000, 6:3696-3704.
86. Baumann L., Vujevich J., Halem M., Martin L.K., Kerdel F., Lazarus M., Pacheco H., Black L., Bryde J. Open-label pilot study of alitretinoin gel 0.1% in the treatment of photoaging. Cutis 2005, 76:69-73.
87. Wan Y.J., Cai Y., Cowan C., Magee T.R. Fatty acyl-CoAs inhibit retinoic acid-induced apoptosis in Hep3B cells. Cancer Lett. 2000, 154:19-27.
88. Lin Y.W., Lien L.M., Yeh T.S., Wu H.M., Liu Y.L., Hsieh R.H. 9-cis retinoic acid induces retinoid X receptor localized to the mitochondria for mediation of mitochondrial transcription. Biochem. Biophys. Res. Commun. 2008, 377:351-354.
89. Zheng Z.S., Xue G.Z., Prystowsky J.H. Regulation of the induction of ornithine decarboxylase in keratinocytes by retinoids. Biochem. J. 1995, 309(Pt 1):159-165.
90. Geiger J.M., Hommel L., Harms M., Saurat J.H. Oral 13-cis retinoic acid is superior to 9-cis retinoic acid in sebosuppression in human beings. J. Am. Acad. Dermatol. 1996, 34:513-515.
91. Bouclier M., Chatelus A., Ferracin J., Delain C., Shroot B., Hensby C.N. Quantification of epidermal histological changes induced by topical retinoids and CD271 in the rhino mouse model using a standardized image analysis technique. Skin Pharmacol. 1991, 4:65-73.
92. Gilgor R.S., Chiaramonti A., Goldsmith L.A., Lazarus G.S. Evaluation of 13-cis retinoic acid in lamellar ichthyosis, pityriasis rubra pilaris and Darier's disease. Cutis 1980, 25:380-381. 385.
93. Thielitz A., Gollnick H. Topical retinoids in acne vulgaris: update on efficacy and safety. Am. J. Clin. Dermatol. 2008, 9:369-381.
94. Van Herle A.J., Agatep M.L., Padua D.N., Totanes T.L., Canlapan D.V., Van Herle H.M., Juillard G.J. Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82W-1) in vitro. J. Clin. Endocrinol. Metab. 1990, 71:755-763.
95. Schreck R., Schnieders F., Schmutzler C., Kohrle J. Retinoids stimulate type I iodothyronine 5'-deiodinase activity in human follicular thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 1994, 79:791-798.
96. Schmutzler C., Koehrle J. Innovative strategies for the treatment of thyroid cancer. Eur. J. Endocrinol. 2000, 143:15-24.
97. Brtko J. Retinoids, rexinoids and their cognate nuclear receptors: character and their role in chemoprevention of selected malignant diseases. Biomed. Pap. Med. Fac. Univ. Palacky, Olomouc, Czech Repub 2007, 151:187-194.
98. Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J. Clin. Oncol. 2009, 27:1007-1013.
99. Huang S., Laoukili J., Epping M.T., Koster J., Holzel M., Westerman B.A., Nijkamp W., Hata A., Asgharzadeh S., Seeger R.C., Versteeg R., Beijersbergen R.L., Bernards R. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009, 15:328-340.
100. Hail N., Kim H.J., Lotan R. Mechanisms of fenretinide-induced apoptosis. Apoptosis 2006, 11:1677-1694.
101. Moon R.C., Pritchard J.F., Mehta R.G., Nomides C.T., Thomas C.F., Dinger N.M. Suppression of rat mammary cancer development by N-(4-hydroxyphenyl)retinamide (4-HPR) following surgical removal of first palpable tumor. Carcinogenesis 1989, 10:1645-1649.
102. Pollard M., Luckert P.H., Sporn M.B. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res. 1991, 51:3610-3611.
103. McCormick D.L., Becci P.J., Moon R.C. Inhibition of mammary and urinary bladder carcinogenesis by a retinoid and a maleic anhydride-divinyl ether copolymer. Carcinogenesis 1982, 3:1473-1476.
104. McCormick D.L., Moon R.C. Antipromotional activity of dietary N-(4-hydroxyphenyl)retinamide in two-stage skin tumorigenesis in CD-1 and SENCAR mice. Cancer Lett. 1986, 31:133-138.
105. McCormick D.L., Moon R.C. Retinoid-tamoxifen interaction in mammary cancer chemoprevention. Carcinogenesis 1986, 7:193-196.
106. Hong W.K., Sporn M.B. Recent advances in chemoprevention of cancer. Science 1997, 278:1073-1077.
107. Formelli F., Barua A.B., Olson J.A. Bioactivities of N-(4-hydroxyphenyl) retinamide and retinoyl beta-glucuronide. FASEB J. 1996, 10:1014-1024.
108. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J. Natl Cancer Inst. 1995, 87:1655-1657.
109. Paulson J.D., Oldham J.W., Preston R.F., Newman D. Lack of genotoxicity of the cancer chemopreventive agent N-(4-hydroxyphenyl)retinamide. Fundam. Appl. Toxicol. 1985, 5:144-150.
110. Abou-Issa H., Moeschberger M., el-Masry W., Tejwani S., Curley R.W., Webb T.E. Relative efficacy of glucarate on the initiation and promotion phases of rat mammary carcinogenesis. Anticancer Res. 1995, 15:805-810.
111. Ohshima M., Ward J.M., Wenk M.L. Preventive and enhancing effects of retinoids on the development of naturally occurring tumors of skin, prostate gland, and endocrine pancreas in aged male ACI/segHapBR rats. J. Natl Cancer Inst. 1985, 74:517-524.
112. McCormick D.L., Bagg B.J., Hultin T.A. Comparative activity of dietary or topical exposure to three retinoids in the promotion of skin tumor induction in mice. Cancer Res. 1987, 47:5989-5993.
113. Chodak G.W. Questioning the value of screening for prostate cancer in asymptomatic men. Urology 1993, 42:116-118.
114. Veronesi U., Paganelli G., Viale G., Galimberti V., Luini A., Zurrida S., Robertson C., Sacchini V., Veronesi P., Orvieto E., De Cicco C., Intra M., Tosi G., Scarpa D. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J. Natl Cancer Inst. 1999, 91:368-373.
115. Chiesa F., Tradati N., Grigolato R., Boracchi P., Biganzoli E., Crose N., Cavadini E., Formelli F., Costa L., Giardini R., Zurrida S., Costa A., De Palo G., Veronesi U. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results. Int. J. Cancer 2005, 115:625-629.
116. Sogno I., Vene R., Sapienza C., Ferrari N., Tosetti F., Albini A. Anti-angiogenic properties of chemopreventive drugs: fenretinide as a prototype. Recent Results Cancer Res. 2009, 181:71-76.
117. Qian J., Zhang J.S., Wang X.Q., Ji J.L., Mei S. Fenretinide stimulates the apoptosis of hepatic stellate cells and ameliorates hepatic fibrosis in mice. Hepatol Res 2009, 39:1229-1247.
118. Preitner F., Mody N., Graham T.E., Peroni O.D., Kahn B.B. Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E1420-E1429.
119. Clifford J.L., Menter D.G., Wang M., Lotan R., Lippman S.M. Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells. Cancer Res. 1999, 59:14-18.
120. Bu P., Wan Y.J. Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer 2007, 7:236.
121. Yang H., Bushue N., Bu P., Yvonne Wan Y.J. Induction and intracellular localization of Nur77 dictate fenretinide-induced apoptosis of human liver cancer cells. Biochem. Pharmacol. 2010, 79:948-954.
122. Li H., Kolluri S.K., Gu J., Dawson M.I., Cao X., Hobbs P.D., Lin B., Chen G., Lu J., Lin F., Xie Z., Fontana J.A., Reed J.C., Zhang X. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science 2000, 289:1159-1164.
123. Holmes W.F., Soprano D.R., Soprano K.J. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J. Cell. Biochem. 2003, 89:262-278.
124. Lin B., Kolluri S.K., Lin F., Liu W., Han Y.H., Cao X., Dawson M.I., Reed J.C., Zhang X.K. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004, 116:527-540.
125. Zhu Y.K., Liu X., Ertl R.F., Kohyama T., Wen F.Q., Wang H., Spurzem J.R., Romberger D.J., Rennard S.I. Retinoic acid attenuates cytokine-driven fibroblast degradation of extracellular matrix in three-dimensional culture. Am. J. Respir. Cell Mol. Biol. 2001, 25:620-627.
126. Garattini E., Parrella E., Diomede L., Gianni M., Kalac Y., Merlini L., Simoni D., Zanier R., Ferrara F.F., Chiarucci I., Carminati P., Terao M., Pisano C. ST1926, a novel and orally active retinoid-related molecule inducing apoptosis in myeloid leukemia cells: modulation of intracellular calcium homeostasis. Blood 2004, 103:194-207.
127. Boisvieux-Ulrich E., Sourdeval M., Marano F. CD437, a synthetic retinoid, induces apoptosis in human respiratory epithelial cells via caspase-independent mitochondrial and caspase-8-dependent pathways both up-regulated by JNK signaling pathway. Exp. Cell Res. 2005, 307:76-90.
128. Farhana L., Dawson M.I., Huang Y., Zhang Y., Rishi A.K., Reddy K.B., Freeman R.S., Fontana J.A. Apoptosis signaling by the novel compound 3-Cl-AHPC involves increased EGFR proteolysis and accompanying decreased phosphatidylinositol 3-kinase and AKT kinase activities. Oncogene 2004, 23:1874-1884.
129. Han Y.H., Cao X., Lin B., Lin F., Kolluri S.K., Stebbins J., Reed J.C., Dawson M.I., Zhang X.K. Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 2006, 25:2974-2986.
130. Qu L., Tang X. Bexarotene: a promising anticancer agent. Cancer Chemother. Pharmacol. 2010, 65:201-205.
131. Minagawa N., Nakayama Y., Inoue Y., Onitsuka K., Katsuki T., Tsurudome Y., Shibao K., Hirata K., Sako T., Nagata N., Ohie S., Kohno K., Itoh H. 4-[3, 5-Bis(trimethylsilyl)benzamido] benzoic acid inhibits angiogenesis in colon cancer through reduced expression of vascular endothelial growth factor. Oncol. Res. 2004, 14:407-414.
132. Higginbotham K.B., Lozano R., Brown T., Patt Y.Z., Arima T., Abbruzzese J.L., Thomas M.B. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 2008, 134:1325-1335.
133. So P.L., Fujimoto M.A., Epstein E.H. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol. Cancer Ther. 2008, 7:1275-1284.
134. Lippman S.M., Sudbo J., Hong W.K. Oral cancer prevention and the evolution of molecular-targeted drug development. J. Clin. Oncol. 2005, 23:346-356.
135. Mao L., El-Naggar A.K., Papadimitrakopoulou V., Shin D.M., Shin H.C., Fan Y., Zhou X., Clayman G., Lee J.J., Lee J.S., Hittelman W.N., Lippman S.M., Hong W.K. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J. Natl Cancer Inst. 1998, 90:1545-1551.
136. Li X.S., Shao Z.M., Sheikh M.S., Eiseman J.L., Sentz D., Jetten A.M., Chen J.C., Dawson M.I., Aisner S., Rishi A.K., et al. Retinoic acid nuclear receptor beta inhibits breast carcinoma anchorage independent growth. J. Cell. Physiol. 1995, 165:449-458.
137. Liu Y., Lee M.O., Wang H.G., Li Y., Hashimoto Y., Klaus M., Reed J.C., Zhang X. Retinoic acid receptor beta mediates the growth-inhibitory effect of retinoic acid by promoting apoptosis in human breast cancer cells. Mol. Cell. Biol. 1996, 16:1138-1149.
138. Li Y., Dawson M.I., Agadir A., Lee M.O., Jong L., Hobbs P.D., Zhang X.K. Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction. Int. J. Cancer 1998, 75:88-95.
139. Pergolizzi R., Appierto V., Crosti M., Cavadini E., Cleris L., Guffanti A., Formelli F. Role of retinoic acid receptor overexpression in sensitivity to fenretinide and tumorigenicity of human ovarian carcinoma cells. Int. J. Cancer 1999, 81:829-834.
140. Campbell M.J., Park S., Uskokovic M.R., Dawson M.I., Koeffler H.P. Expression of retinoic acid receptor-beta sensitizes prostate cancer cells to growth inhibition mediated by combinations of retinoids and a 19-nor hexafluoride vitamin D3 analog. Endocrinology 1998, 139:1972-1980.
141. Ferrari N., Pfahl M., Levi G. Retinoic acid receptor gamma1 (RARgamma1) levels control RARbeta2 expression in SK-N-BE2(c) neuroblastoma cells and regulate a differentiation-apoptosis switch. Mol. Cell. Biol. 1998, 18:6482-6492.
142. Hoffman A.D., Engelstein D., Bogenrieder T., Papandreou C.N., Steckelman E., Dave A., Motzer R.J., Dmitrovsky E., Albino A.P., Nanus D.M. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin. Cancer Res. 1996, 2:1077-1082.
143. Kaiser A., Herbst H., Fisher G., Koenigsmann M., Berdel W.E., Riecken E.O., Rosewicz S. Retinoic acid receptor beta regulates growth and differentiation in human pancreatic carcinoma cells. Gastroenterology 1997, 113:920-929.
144. Li C., Wan Y.J. Differentiation and antiproliferation effects of retinoic acid receptor beta in hepatoma cells. Cancer Lett. 1998, 124:205-211.
145. Hayashi K., Yokozaki H., Naka K., Yasui W., Lotan R., Tahara E. Overexpression of retinoic acid receptor beta induces growth arrest and apoptosis in oral cancer cell lines. Jpn J. Cancer Res. 2001, 92:42-50.
146. Xu X.C., Zile M.H., Lippman S.M., Lee J.S., Lee J.J., Hong W.K., Lotan R. Anti-retinoic acid (RA) antibody binding to human premalignant oral lesions, which occurs less frequently than binding to normal tissue, increases after 13-cis-RA treatment in vivo and is related to RA receptor beta expression. Cancer Res. 1995, 55:5507-5511.
147. Berard J., Gaboury L., Landers M., De Repentigny Y., Houle B., Kothary R., Bradley W.E. Hyperplasia and tumours in lung, breast and other tissues in mice carrying a RAR beta 4-like transgene. EMBO J. 1994, 13:5570-5580.
148. Lotan R., Xu X.C., Lippman S.M., Ro J.Y., Lee J.S., Lee J.J., Hong W.K. Suppression of retinoic acid receptor-beta in premalignant oral lesions and its up-regulation by isotretinoin. N Engl J. Med. 1995, 332:1405-1410.
149. Shin D.M., Xu X.C., Lippman S.M., Lee J.J., Lee J.S., Batsakis J.G., Ro J.Y., Martin J.W., Hittelman W.N., Lotan R., Hong W.K. Accumulation of p53 protein and retinoic acid receptor beta in retinoid chemoprevention. Clin. Cancer Res. 1997, 3:875-880.
150. Youssef E.M., Lotan D., Issa J.P., Wakasa K., Fan Y.H., Mao L., Hassan K., Feng L., Lee J.J., Lippman S.M., Hong W.K., Lotan R. Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis. Clin. Cancer Res. 2004, 10:1733-1742.
151. Cras A., Darsin-Bettinger D., Balitrand N., Cassinat B., Soulie A., Toubert M.E., Delva L., Chomienne C. Epigenetic patterns of the retinoic acid receptor beta2 promoter in retinoic acid-resistant thyroid cancer cells. Oncogene 2007, 26:4018-4024.
152. Darwiche N., Celli G., Tennenbaum T., Glick A.B., Yuspa S.H., De Luca L.M. Mouse skin tumor progression results in differential expression of retinoic acid and retinoid X receptors. Cancer Res. 1995, 55:2774-2782.
153. Lotan R. Retinoids in cancer chemoprevention. FASEB J. 1996, 10:1031-1039.
154. Fisher G.J., Datta S.C., Talwar H.S., Wang Z.Q., Varani J., Kang S., Voorhees J.J. Molecular basis of sun-induced premature skin ageing and retinoid antagonism. Nature 1996, 379:335-339.
155. Fisher G.J., Talwar H.S., Lin J., Lin P., McPhillips F., Wang Z., Li X., Wan Y., Kang S., Voorhees J.J. Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J. Clin. Invest. 1998, 101:1432-1440.
156. Wang Z., Boudjelal M., Kang S., Voorhees J.J., Fisher G.J. Ultraviolet irradiation of human skin causes functional vitamin A deficiency, preventable by all-trans retinoic acid pre-treatment. Nat. Med. 1999, 5:418-422.
157. Greenhalgh D.A., Welty D.J., Player A., Yuspa S.H. Two oncogenes, v-fos and v-ras, cooperate to convert normal keratinocytes to squamous cell carcinoma. Proc. Natl Acad. Sci. USA 1990, 87:643-647.
158. Leder A., Kuo A., Cardiff R.D., Sinn E., Leder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl Acad. Sci. USA 1990, 87:9178-9182.
159. Huang C., Ma W.Y., Dawson M.I., Rincon M., Flavell R.A., Dong Z. Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc. Natl Acad. Sci. USA 1997, 94:5826-5830.
160. Chen J.Y., Penco S., Ostrowski J., Balaguer P., Pons M., Starrett J.E., Reczek P., Chambon P., Gronemeyer H. RAR-specific agonist/antagonists which dissociate transactivation and AP1 transrepression inhibit anchorage-independent cell proliferation. EMBO J. 1995, 14:1187-1197.
161. Kang S., Bergfeld W., Gottlieb A.B., Hickman J., Humeniuk J., Kempers S., Lebwohl M., Lowe N., McMichael A., Milbauer J., Phillips T., Powers J., Rodriguez D., Savin R., Shavin J., Sherer D., Silvis N., Weinstein R., Weiss J., Hammerberg C., Fisher G.J., Nighland M., Grossman R., Nyirady J. Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trial. Am. J. Clin. Dermatol. 2005, 6:245-253.
162. Blot W.J., Li J.Y., Taylor P.R., Guo W., Dawsey S., Wang G.Q., Yang C.S., Zheng S.F., Gail M., Li G.Y., et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J. Natl Cancer Inst. 1993, 85:1483-1492.
163. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J. Med. 1994, 330:1029-1035.
164. Omenn G.S., Goodman G.E., Thornquist M.D., Balmes J., Cullen M.R., Glass A., Keogh J.P., Meyskens F.L., Valanis B., Williams J.H., Barnhart S., Hammar S. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J. Med. 1996, 334:1150-1155.
165. Hennekens C.H., Buring J.E., Manson J.E., Stampfer M., Rosner B., Cook N.R., Belanger C., LaMotte F., Gaziano J.M., Ridker P.M., Willett W., Peto R. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J. Med. 1996, 334:1145-1149.
166. De Vries N., Van Zandwijk N., Pastorino U. The EUROSCAN study: a progress report. Am. J. Otolaryngol. 1993, 14:62-66.
167. Whang-Peng J., Kao-Shan C.S., Lee E.C., Bunn P.A., Carney D.N., Gazdar A.F., Minna J.D. Specific chromosome defect associated with human small-cell lung cancer; deletion 3p(14-23). Science 1982, 215:181-182.
168. Houle B., Leduc F., Bradley W.E. Implication of RARB in epidermoid (Squamous) lung cancer. Genes Chromosom. Cancer 1991, 3:358-366.
169. Picard E., Seguin C., Monhoven N., Rochette-Egly C., Siat J., Borrelly J., Martinet Y., Martinet N., Vignaud J.M. Expression of retinoid receptor genes and proteins in non-small-cell lung cancer. J. Natl Cancer Inst. 1999, 91:1059-1066.
170. Xu X.C., Sozzi G., Lee J.S., Lee J.J., Pastorino U., Pilotti S., Kurie J.M., Hong W.K., Lotan R. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J. Natl Cancer Inst. 1997, 89:624-629.
171. Xu X.C., Ro J.Y., Lee J.S., Shin D.M., Hong W.K., Lotan R. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res. 1994, 54:3580-3587.
172. Widschwendter M., Berger J., Daxenbichler G., Muller-Holzner E., Widschwendter A., Mayr A., Marth C., Zeimet A.G. Loss of retinoic acid receptor beta expression in breast cancer and morphologically normal adjacent tissue but not in the normal breast tissue distant from the cancer. Cancer Res. 1997, 57:4158-4161.
173. Tyagi P. Bexarotene in combination with chemotherapy fails to prolong survival in patients with advanced non-small-cell lung cancer: results from the SPIRIT I and II trials. Clin. Lung Cancer 2005, 7:17-19.
174. Crowe D.L. Receptor selective synthetic retinoids as potential cancer chemotherapy agents. Curr. Cancer Drug Targets 2002, 2:77-86.
175. Petty W.J., Li N., Biddle A., Bounds R., Nitkin C., Ma Y., Dragnev K.H., Freemantle S.J., Dmitrovsky E. A novel retinoic acid receptor beta isoform and retinoid resistance in lung carcinogenesis. J. Natl Cancer Inst. 2005, 97:1645-1651.
176. Wu Q., Li Y., Liu R., Agadir A., Lee M.O., Liu Y., Zhang X. Modulation of retinoic acid sensitivity in lung cancer cells through dynamic balance of orphan receptors nur77 and COUP-TF and their heterodimerization. EMBO J. 1997, 16:1656-1669.
177. Lin B., Chen G.Q., Xiao D., Kolluri S.K., Cao X., Su H., Zhang X.K. Orphan receptor COUP-TF is required for induction of retinoic acid receptor beta, growth inhibition, and apoptosis by retinoic acid in cancer cells. Mol. Cell. Biol. 2000, 20:957-970.
178. Veronesi U., Mariani L., Decensi A., Formelli F., Camerini T., Miceli R., Di Mauro M.G., Costa A., Marubini E., Sporn M.B., De Palo G. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann. Oncol. 2006, 17:1065-1071.
179. Zanardi S., Serrano D., Argusti A., Barile M., Puntoni M., Decensi A. Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer 2006, 13:51-68.
180. Macejova D., Baranova M., Liska J., Brtko J. Expression of nuclear hormone receptors, their coregulators and type I iodothyronine 5'-deiodinase gene in mammary tissue of nonlactating and postlactating rats. Life Sci. 2005, 77:2584-2593.
181. Wang Y., Zhang J.J., Dai W., Pike J.W. Production of granulocyte colony-stimulating factor by THP-1 cells in response to retinoic acid and phorbol ester is mediated through the autocrine production of interleukin-1. Biochem. Biophys. Res. Commun. 1996, 225:639-646.
182. Zhang X.K., Liu Y., Lee M.O. Retinoid receptors in human lung cancer and breast cancer. Mutat. Res. 1996, 350:267-277.
183. Gottardis M.M., Bischoff E.D., Shirley M.A., Wagoner M.A., Lamph W.W., Heyman R.A. Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 1996, 56:5566-5570.
184. Anzano M.A., Byers S.W., Smith J.M., Peer C.W., Mullen L.T., Brown C.C., Roberts A.B., Sporn M.B. Prevention of breast cancer in the rat with 9-cis-retinoic acid as a single agent and in combination with tamoxifen. Cancer Res. 1994, 54:4614-4617.
185. Zujewski J., Pai L., Wakefield L., Giusti R., Dorr F.A., Flanders C., Caruso R., Kaiser M., Goodman L., Merino M., Gossard M., Noone M.A., Denicoff A., Venzon D., Cowan K.H., O'Shaughnessy J.A. Tamoxifen and fenretinide in women with metastatic breast cancer. Breast Cancer Res. Treat. 1999, 57:277-283.
186. Liu L., Gudas L.J. Retinoic acid induces expression of the interleukin-1beta gene in cultured normal human mammary epithelial cells and in human breast carcinoma lines. J. Cell. Physiol. 2002, 193:244-252.
187. Fabian C.J., Kimler B.F. Chemoprevention for high-risk women: tamoxifen and beyond. Breast J. 2001, 7:311-320.
188. Li Y., Brown P.H. Prevention of ER-negative breast cancer. Recent Results Cancer Res. 2009, 181:121-134.
189. Raif A., Marshall G.M., Bell J.L., Koach J., Tan O., D'Andreti C., Thomas W., Sekyere E., Norris M., Haber M., Kavallaris M., Cheung B.B. The estrogen-responsive B box protein (EBBP) restores retinoid sensitivity in retinoid-resistant cancer cells via effects on histone acetylation. Cancer Lett. 2009, 277:82-90.
190. Yang X., Guo M., Wan Y.J. Deregulation of growth factor, circadian clock, and cell cycle signaling in regenerating hepatocyte RXRalpha-deficient mouse livers. Am. J. Pathol. 2010, 176:733-743.
191. N. Bushue and Y. J. Wan, Retinoic acid-mediated nuclear receptor activation and hepatocyte proliferation, 1 (2009) 23-30.
192. Theodosiou M., Laudet V., Schubert M. From carrot to clinic: an overview of the retinoic acid signaling pathway. Cell. Mol. Life Sci. 2010.
193. Vuletic A., Konjevic G., Milanovic D., Ruzdijic S., Jurisic V. Antiproliferative effect of 13-cis-retinoic acid is associated with granulocyte differentiation and decrease in cyclin B1 and Bcl-2 protein levels in G0/G1 arrested HL-60 cells. Pathol. Oncol. Res. 2010.
194. Varani J., Fay K., Perone P. MDI 301, a non-irritating retinoid, induces changes in human skin that underlie repair. Arch. Dermatol. Res. 2007, 298:439-448.
195. Chiu Y.Y., Roth M.D., Kolis S., Rogovitz D., Davies B. Pharmacokinetics of a novel agent, R667, in patients with emphysema. Br. J. Clin. Pharmacol. 2007, 63:527-533.
196. Hansen N.J., Wylie R.C., Phipps S.M., Love W.K., Andrews L.G., Tollefsbol T.O. The low-toxicity 9-cis UAB30 novel retinoid down-regulates the DNA methyltransferases and has anti-telomerase activity in human breast cancer cells. Int. J. Oncol. 2007, 30:641-650.
197. Jiang W., Deng W., Bailey S.K., Nail C.D., Frost A.R., Brouillette W.J., Muccio D.D., Grubbs C.J., Ruppert J.M., Lobo-Ruppert S.M. Prevention of KLF4-mediated tumor initiation and malignant transformation by UAB30 rexinoid. Cancer Biol. Ther. 2009, 8:289-298.
198. Piskin S., Uzunali E. A review of the use of adapalene for the treatment of acne vulgaris. Ther. Clin. Risk Manage. 2007, 3:621-624.
199. Yin J.J., Xia Q., Fu P.P. UVA photoirradiation of anhydroretinol-formation of singlet oxygen and superoxide. Toxicol. Ind. Health 2007, 23:625-631.
200. Zhang X.K. Targeting Nur77 translocation. Expert Opin. Ther. Targets 2007, 11:69-79.
201. Zhang Y., Soto J., Park K., Viswanath G., Kuwada S., Abel E.D., Wang L. Nuclear receptor SHP, a death receptor that targets mitochondria, induces apoptosis and inhibits tumor growth. Mol. Cell. Biol. 2010.
202. Zuco V., Benedetti V., De Cesare M., Zunino F. Sensitization of ovarian carcinoma cells to the atypical retinoid ST1926 by the histone deacetylase inhibitor, RC307: enhanced DNA damage response. Int. J. Cancer 2010, 126:1246-1255.
203. Farhana L., Dawson M.I., Dannenberg J.H., Xu L., Fontana J.A. SHP and Sin3A expression are essential for adamantyl-substituted retinoid-related molecule-mediated nuclear factor-kappaB activation, c-Fos/c-Jun expression, and cellular apoptosis. Mol. Cancer Ther. 2009, 8:1625-1635.
204. Perez-Rodriguez S., Ortiz M.A., Pereira R., Rodriguez-Barrios F., de Lera A.R., Piedrafita F.J. Highly twisted adamantyl arotinoids: synthesis, antiproliferative effects and RXR transactivation profiles. Eur. J. Med. Chem. 2009, 44:2434-2446.
205. Komi Y., Sogabe Y., Ishibashi N., Sato Y., Moriwaki H., Shimokado K., Kojima S. Acyclic retinoid inhibits angiogenesis by suppressing the MAPK pathway. Lab Invest 2010, 90:52-60.
206. Shimizu M., Takai K., Moriwaki H. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention. Cancer Sci. 2009, 100:369-374.
207. Chengedza S., Benbrook D.M. NF-kappaB is involved in SHetA2 circumvention of TNF-alpha resistance, but not induction of intrinsic apoptosis. Anticancer Drugs 2010, 21:297-305.